"Mount Sinai Awarded $10 Million Grant To Explore Cellular, Molecular Mechanisms Of GVHD"
Researchers from the Icahn School of Medicine at Mount Sinai have been awarded a $10 million from the National Cancer Institute to explore the cellular and molecular mechanisms of acute graft-versus-host disease (GVHD), a common side effect that occurs after allogeneic bone marrow transplantation (BMT), and to develop novel therapeutic strategies for BMT patients with cancer that begin in the cells of blood-forming tissue or hematologic malignancies. "My colleagues and I have developed an exciting prognostic tool to identify those who will get GVHD and those who will not," said James L. M. Ferrara, MD, professor of oncological sciences at the Icahn School of Medicine at Mount Sinai. "In doing so, we will design treatment to respond to each patient's disease progression and possibly stop its escalation. The studies are highly significant and translational, and have the potential to impact patients' care." Learn more.